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Saturated fats, dairy foods and health:
A curious paradox?
D. I. Givens
Institute of Food, Nutrition and Health, University of Reading, Reading, UK
Abstract Cardiovascular diseases (CVD) remain a major cause of death and morbidity
worldwide. Dietary guidelines aim to restrict the intake of saturated fatty acids
(SFA) as they are regarded as an important risk factor for CVD due to their
association with increased blood cholesterol. As dairy foods are major
contributors of dietary SFA, there have been guidelines to reduce consumption of
these foods. However, it is now generally accepted that the effects of reducing
intake of SFA are dependent on what replaces them in the diet. Reduced CVD
risk has been associated with replacement of SFA with cis-polyunsaturated fatty
acids (cis-PUFA) and/or cis-monounsaturated fatty acids (cis-MUFA), with
replacement by carbohydrate leading to no reduction or even increased CVD
risk. Most studies on the effect of diet/food on CVD risk have used total
cholesterol (TC) and/or low-density lipoprotein cholesterol (LDL-C) in blood as
the marker(s) of risk. However, because of potentially attenuating effects of dairy
foods (e.g. effect of protein on blood lipids and blood pressure; food matrix
effects on fat bioavailability), a wider range of markers is needed to more fully
evaluate disease risk. Nevertheless, whilst prospective evidence shows no increase
in CVD risk from high dairy consumption, it is still unclear whether replacing a
proportion of SFA in dairy fat with cis-MUFA will lead to reduced CVD risk.
The relatively few randomised controlled trials that have examined this using
TC/LDL-C as risk markers give some indications of reduced CVD risk from
consumption of milk and dairy products with modified fatty acid composition,
compared with those of normal milk fat composition. The results of ongoing
studies will add valuable new evidence on this issue.
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Introduction
Despite improved prevention and treatment pro-
grammes, cardiovascular disease (CVD) remains a
major cause of death and morbidity in the European
Union (EU) (Wilkins et al. 2017) and worldwide
(Forouzanfar et al. 2015). Although CVD mortality is
now decreasing in most European countries, there are
some 49 million people living with CVD in the EU
with an estimated cost of €210 billion/year (Wilkins
et al. 2017). Moreover, the increase in prevalence of
overweight/obesity and type 2 diabetes seen in the EU
in recent times casts doubt on whether the current
reduction in CVD mortality is sustainable. It is there-
fore imperative that modifiable risk factors for CVD,
such as diet, are used to their full advantage.
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A high intake of saturated fatty acids (SFA) has for
many years been regarded as an important risk factor
for CVD, leading to public health targets recommend-
ing a dietary SFA intake that should not be exceeded.
In the UK, this recommendation, currently being
reviewed, is that SFA intake should not exceed 11%
of food energy intake but, as shown in Table 1, intake
for all age groups in the National Diet and Nutrition
Survey (Bates et al. 2014) exceeds this target. Table 1
also shows that milk and dairy products (including
butter) are major sources of dietary SFA and this has
led to some proposals to reduce dairy product con-
sumption in order to reduce SFA intake. Recent evi-
dence suggests that this approach is likely to be too
simplistic (Thorning et al. 2017).
Effects of saturated fat consumption
Recent meta-analyses of prospective studies (Siri-Tarino
et al. 2010; Chowdhury et al. 2014; de Souza et al.
2015) have raised doubts about whether a high intake
of SFA is a risk factor for CVD. The specific effect of
SFA on CVD risk is well established and is mainly
mediated via increases in blood lipids, particularly
low-density lipoprotein cholesterol (LDL-C) (Griffin
2017). There is strong evidence implicating LDL-C as
a risk factor in CVD events (Ridker 2014) and ran-
domised controlled trials (RCT) with LDL-C lowering
interventions have confirmed a causal relationship
between blood LDL-C and CVD, particularly coro-
nary heart disease (CHD; Marz et al. 2016). However,
as highlighted by Mensink et al. (2003), SFA can also
increase high-density lipoprotein cholesterol (HDL-C),
generally regarded as being associated with reduced
CVD risk. It should also be noted that blood LDL-C
contains the cholesterol present in all LDL particles,
with the small, dense LDL particles (sdLDL), whilst
containing less cholesterol per particle than other LDL
particles, are more strongly associated with increased
CHD risk than the larger less dense LDL particles
(Hoogeveen et al. 2014). One cross-sectional study in
healthy Swedish men indicated that dietary fatty acids
typically found in dairy foods gave rise to significantly
less sdLDL particles (Sjogren et al. 2004). In particu-
lar, SFA 4:0 to 10:0 and 14:0 (P <0.05) in the diet
and 15:0 and 17:0 (markers of dairy fat intake) in
serum phospholipids (P <0.05) were associated with
fewer sdLDL particles. This study suggests that LDL
particle size distribution may be favourably modified
by dairy products in the diet but this needs further
investigation.
Substitution of dietary saturated fatty acids with
unsaturated fatty acids
As noted above, data from prospective studies (Siri-
Tarino et al. 2010; de Souza et al. 2015) have cast
doubts on the traditional view of SFA as a risk fac-
tor for CVD. Recently, an expert group met to
review this conflict (Nettleton et al. 2017). Their key
recommendation was that it is vitally important to
understand the effect of replacing SFA in the diet.
Nettleton et al. (2017) concluded that the greatest
reduction in CHD risk was seen when dietary SFA
are replaced with cis-polyunsaturated fatty acids (cis-
PUFA) although there was little effect on risk of
stroke. They cited RCTs which showed that replace-
ment of 10% and 5% of energy from SFA by cis-
PUFA reduced CVD events by 27% and 10%,
respectively. It is also noteworthy that replacement of
SFA with refined carbohydrate is associated with no
improvement or even an increase in CVD risk (Micha
& Mozaffarian 2010).
Nettleton et al. (2017) also reported that there are
insufficient data to draw conclusions on the effect of
replacing SFA with cis-MUFA, although there are a
number of important studies. A cross-sectional popu-
lation study by Miura et al. (2013) reported a linear
inverse association between cis-MUFA (especially oleic
acid) intake and diastolic blood pressure, and in the
recruited population study of Hassan et al. (2015),
dietary oleic acid intake was negatively associated
with systolic and diastolic blood pressure. Recently,
the RCT of Liu et al. (2016) compared diets high in
cis-PUFA with those high in cis-MUFA and showed
that the latter reduced abdominal obesity with accom-
panying reductions in blood pressure and blood
Table 1 Mean daily intake of saturated fatty acids (SFA) and as a
percentage of food energy (FE) and total energy (TE) by gender
and age, together with the contribution of dairy foods to SFA
intake in the UK (from Bates et al. 2014)
Males (years of age) Females (years of age)
4–10 11–18 19–64 65+ 4–10 11–18 19–64 65+
SFA (g/day) 23.0 27.8 28.4 28.7 22.3 21.7 22.1 23.0
SFA % FE 13.1 12.7 12.6 13.9 13.3 12.4 12.6 13.8
SFA % TE 13.1 12.6 11.9 13.2 13.3 12.3 12.1 13.5
Contribution
of dairy
foods to
total SFA
intake (%)
34 26 25 34 41 25 28 36
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triacylglycerols (TAG). The Reading, Imperial, Surrey,
Cambridge, and Kings (RISCK) study (Jebb et al.
2010) showed that replacing SFA with cis-MUFA,
compared to replacement with carbohydrate, reduced
the total cholesterol (TC):HDL-C ratio and, more
recently, the Dietary Intervention and VAScular func-
tion (DIVAS) study (Vafeiadou et al. 2015) showed
that replacement of about 9.6% of energy from SFA
by MUFA lowered serum TC by 8.4%, LDL-C by
11.3% and TC:HDL-C by 5.6% (P <0.001). Thus,
overall, there is mounting evidence that replacing diet-
ary SFA with cis-MUFA may be beneficial for reduc-
ing the risk of CVD and associated factors in the
metabolic syndrome.
Dairy consumption and cardiometabolic
disease
Evidence from prospective cohort studies
Numerous studies have investigated the association
between milk and dairy product consumption and car-
diometabolic diseases (CMD; CVD + type 2 diabetes).
Whilst prospective study data are regarded as provid-
ing weaker evidence than RCT data on the diet/food–
disease relationship, they have the advantage of look-
ing at long-term effects and use real disease events as
the outcome measures. Very long-term RCTs using
disease data would be impractical and very expensive,
and this means that most RCTs use markers of disease
risk (e.g. LDL-C) as primary outcome measures.
Meta-analysis of prospective studies is a valuable tool
for looking at the overall association between dairy
foods and CMD risk, although there remains a con-
cern that in many studies the dairy foods involved are
poorly defined which limits assessment of the relative
effects of different dairy foods. This is particularly the
case when comparing high-fat vs. low-fat dairy prod-
ucts. Early meta-analyses of prospective cohort studies
reported that, overall, high milk consumption does
not increase the relative risk (RR) of CHD (Elwood
et al. 2008, 2010). A further meta-analysis, which
combined prospective cohort and clinical studies, also
indicated no significant increase in the RR of CHD in
high vs. low milk consumers (RR 0.94; 95% CI,
0.75–1.13) (Mente et al. 2009).
A number of dose–response meta-analyses have
been published recently examining the association
between dairy food consumption and type 2 diabetes
(Gijsbers et al. 2016), stroke (de Goede et al. 2016),
and CVD and all-cause mortality (Guo et al. 2017).
These are the most up-to-date dose–response
meta-analyses available and the results are summarised
in Table 2. Overall, these studies show no increase in
risk of CVD per unit increase in milk and cheese con-
sumptions and a significant reduction in risk of stroke
per unit consumption of cheese and milk. Interest-
ingly, yoghurt consumption was associated with a
reduced risk of type 2 diabetes (Gijsbers et al. 2016).
There are few studies examining the effects of butter
on CMD but the recent dose–response meta-analysis
of Pimpin et al. (2016) indicates no significant associa-
tion between butter consumption and all-cause mortal-
ity, CVD, CHD or stroke, although there was a
significant negative association with type 2 diabetes
(Table 2). The meta-analysis of Pimpin et al. (2016)
involved relatively few cohorts for CVD (n = 4), CHD
(n = 3), stroke (n = 3) although 11 cohorts were suit-
able for inclusion for type 2 diabetes.
Evidence from randomised controlled trials
Given the evidence linking SFA intake with blood
levels of LDL-C, and blood levels of LDL-C with
CVD risk, and the fact that dairy foods are major con-
tributors to SFA, the consistent neutral or beneficial
associations between dairy foods and CVD from anal-
ysis of prospective data remain something of a para-
dox to many. There is, however, increasing evidence
Table 2 Recent dose–response meta-analyses examining the rela-
tive risk (RR) of cardiometabolic disease in relation to consumption
of dairy foods
Dairy food Outcome RR (95% CI) Reference
Milk (per 244 g/day) All-cause
mortality
1.00 (0.93–1.07) Guo et al. (2017)
Milk (per 244 g/day) CVD 1.01 (0.93–1.10) Guo et al. (2017)
Cheese (per 10 g/day) CVD 0.98 (0.95–1.00) Guo et al. (2017)
Yoghurt (per 50 g/day) CVD 1.03 (0.97–1.09 Guo et al. (2017)
Milk (per 200 g/day) Stroke 0.93 (0.88–0.98) de Goede et al.
(2016)
Cheese (per 40 g/day) Stroke 0.97 (0.94–1.01) de Goede et al.
(2016)
Yoghurt (per 80 g/day) Type 2
diabetes
0.86 (0.83–0.90) Gijsbers et al.
(2016)
Butter (per 14 g/day) All-cause
mortality
1.01 (1.00–1.03) Pimpin et al. (2016)
Butter (per 14 g/day) CVD 1.00 (0.98–1.02) Pimpin et al. (2016)
Butter (per 14 g/day) CHD 0.99 (0.96–1.03) Pimpin et al. (2016)
Butter (per 14 g/day) Stroke 1.01 (0.93–0.99) Pimpin et al. (2016)
Butter (per 14 g/day) Type 2
diabetes
0.96 (0.93–0.99) Pimpin et al. (2016)
CI, conﬁdence interval; CVD, cardiovascular disease; CHD, coronary heart
disease.
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that goes some way to explain why meta-analyses of
prospective studies show no increased risk of CVD in
high dairy consumers.
In the UK, up to 30% of adults are hypertensive
(Townsend et al. 2015) and hypertension is one of the
major risk factors for CVD development and stroke,
in particular. Gene polymorphisms, nutrition, the envi-
ronment and interactions between these factors con-
tribute to the development of hypertension. Milk and
milk-derived products provide essential micronutrients
(e.g. calcium, magnesium, iodine and vitamin D) and
proteins (whey, casein and specific bioactive peptides)
some of which have been associated with beneficial
hypotensive effects, either independently or in combi-
nation within dairy foods (Kris-Etherton et al. 2009).
A recent 8-week RCT (Fekete et al. 2016) showed that
whey protein isolate (two doses of 28 g, mixed with
water, per day) had a greater hypotensive effect than
casein and the effects were seen on both central and
peripheral blood pressures. A number of mechanisms
by which milk and its components could lower blood
pressure (BP) have been proposed (Fekete et al. 2013).
Peptides released during digestion of casein and whey
proteins have been shown to have hypotensive effects
by inhibiting the action of angiotensin-I-converting
enzyme, resulting in vasodilation (FitzGerald & Meisel
2000) by modulating the release of endothelin-1 by
endothelial cells (Maes et al. 2004) and acting as opi-
oid receptor ligands increasing nitric oxide production,
which mediates arterial tone (Kris-Etherton et al.
2009). There is little firm evidence for differential
effects of low- vs. high-fat dairy foods on hyperten-
sion. For example, whilst Engberink et al. (2009)
reported an inverse association between low-fat dairy
intake and risk of hypertension in older adults, others
have shown that both low- and high-fat milk products
have hypotensive effects (Ralston et al. 2012). In addi-
tion, results from the Caerphilly Prospective Study
showed that when compared with non-milk con-
sumers, men who consumed >586 ml/day of milk had
on average a 10.4 mmHg lower systolic BP after a
22.8-year follow-up (Livingstone et al. 2013). Some of
the inconsistencies between studies may well relate to
the lack of a consistent definition of what constitutes
low- and high-fat dairy foods.
There is now good evidence that arterial stiffness,
especially of the large vessels, is an important predic-
tor of CVD events (Cockcroft & Wilkinson 2000) and
this can be affected by dietary patterns (Kesse-Guyot
et al. 2010). The measurement of carotid-femoral
pulse wave velocity (PWV) is regarded as the gold
standard for assessing arterial stiffness and can
independently predict CVD events (Sutton-Tyrrell
et al. 2005; Van Bortel et al. 2012). Livingstone et al.
(2013), using data from the Caerphilly Prospective
Study, showed for the first time in a longitudinal study
that dairy product consumption (not including butter)
does not increase PWV (i.e. no indication of increased
arterial stiffness). Moreover, the measurement of aug-
mentation index, another indicator of arterial stiffness,
was 1.9% units lower (P = 0.021) in men with the
highest dairy consumption (Livingstone et al. 2013). A
cross-sectional study also reported that consumption
of dairy foods was negatively associated with PWV
(Crichton et al. 2012).
Food matrix effects of dairy products on blood lipids
Traditional nutritional evaluation of foods and diets
and their relationship with the health of the consumer
has generally been based on separate assessments of
individual food components such as protein, fat, car-
bohydrates and micronutrients. This approach of asso-
ciating one nutrient to one health effect (e.g. SFA
intake to CVD risk) may explain some of the discrep-
ancies between a food’s predicted health effect, based
on its nutrient content, and its actual health effect
when consumed as a whole food. There is increasing
evidence that for an accurate evaluation of the health
effects of some dairy foods, the so-called food matrix
does indeed need to be taken into account. This topic
has recently been extensively reviewed by a Working
Party set up by the Universities of Copenhagen and
Reading, and the conclusions are reported by Thorn-
ing et al. (2017). The Working Party concluded that
‘Evidence to date indicates the dairy matrix has speci-
fic beneficial effects on health, as the metabolic impact
of whole dairy on bodyweight, cardiometabolic dis-
ease risk, and bone health differ to that of single dairy
constituents. Also, different types of dairy products
seem to be distinctly linked to various health effects
and disease risk markers. In addition, different pro-
cessing methods and dairy structures can enhance
interactions in the dairy matrix, thereby modifying the
metabolic effects of dairy consumption. The nutri-
tional value of dairy products should therefore be con-
sidered as the biofunctionality of the sum of nutrients
within the dairy matrix structures’.
A good example of the differential effects on blood
lipids of SFA intake from cheese and butter is shown
in the RCT of Hjerpsted et al. (2011), which consisted
of two 6-week crossover periods with 49 men and
women replacing part of their habitual dietary fat
with 13% of energy from cheese or butter (80 g/day
© 2017 The Authors. Nutrition Bulletin published by John Wiley & Sons Ltd on behalf of British Nutrition Foundation Nutrition Bulletin, 42, 274–282
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and 36 g/day of total fat and SFA, respectively). The
cheese and butter diets provided 1192 g and 417 g of
calcium/day, respectively. Relative to baseline, cheese
did not increase TC or LDL-C whereas butter
increased both (P <0.001 and <0.05, respectively), and
additionally cheese intake led to a 5.7% and 6.9%
lower TC and LDL-C concentrations, respectively
(P <0.0001), compared with butter. Various mecha-
nisms have been suggested as being responsible for the
health benefits of this so-called matrix effect, and the
study of Lorenzen and Astrup (2011) identified mecha-
nisms which could contribute to the differential effects
of cheese and butter on blood cholesterol. They ran-
domised study participants to one of four isoenergetic
diets comprising low-fat (25% energy intake) and
high-fat diets (40% energy intake), each of which con-
tained either low (700 mg/day) or high (2800 mg/day)
calcium. The key results are summarised in Table 3.
Increasing calcium intake increased faecal fat and bile
acid excretion in both low- and high-fat diets,
although the high-fat diets also increased faecal fat
loss. Lorenzen and Astrup (2011) proposed that the
key effect of calcium on faecal fat and bile acid excre-
tion is likely to be the result of formation of insoluble
calcium-fatty acid soaps and/or of hydrophobic aggre-
gations with phosphorus and bile acids. Increased fae-
cal fat excretion is indicative of reduced fat absorption
and hence a moderated blood cholesterol response,
whilst increased bile acid excretion would reduce the
amount that was recycled via the enterohepatic circu-
lation. Reduced bile acid recycling would lead to
increased metabolism of cholesterol for bile acid syn-
thesis, thus reducing that in the circulation.
These studies indicate that the impact of dairy foods
on CVD risk factors may be dependent on the food
matrix, even for dairy foods that supply the same
amount of dairy fat and SFA. However, as concluded
by Thorning et al. (2017), further work is needed to
fully understand food matrix effects on health and
how these relate to specific dairy foods and methods
of processing.
Effects of milk proteins on blood lipids
Whilst most studies have reported on the effect of
dairy fat/fatty acids on blood lipids, there is now evi-
dence that milk proteins can also influence blood
lipids. The study of Tong et al. (2014), using a high-
fat diet with rats, found that whey protein signifi-
cantly increased HDL-C, although studies with
humans have not always shown the same effect (Chiu
et al. 2014). Some studies have shown that whey pro-
tein tends to reduce plasma TAG (Pal et al. 2010) and
TC (Petyaev et al. 2012). The study of Mariotti et al.
(2015) showed that compared with whey protein,
casein markedly reduced postprandial TAG
(22  10% reduction in the 6-hour area under the
curve, P <0.05). Similar effects were seen for plasma
chylomicrons (apoB-48; P <0.05). The recent study of
Fekete et al. (2016) reported that whilst whey protein
and calcium caseinate both significantly reduced TC
(20.26 mmol/l, P = 0.013 and 20.20 mmol/l,
P = 0.042, respectively), only whey protein reduced
TAG (20.23 mmol/l, P = 0.025) compared with the
control.
Overall, these studies indicate that milk proteins can
have important lowering effects on blood lipids, which
may moderate any opposite effects of dairy fats and
be a contributing factor to the neutral or health bene-
fits of dairy foods observed in prospective studies.
Nevertheless, it is clear that more work in this area is
needed and supports the proposal of Lovegrove and
Givens (2016) for a meta-analysis of effects of milk
proteins on blood lipids.
Replacing saturated fatty acids in milk fat
by modifying the diet of the dairy cow
Milk fat per 100 g typically contains 70–75 g SFA,
20–25 g cis-MUFA and small (2–5 g) amounts of cis-
PUFA (Kliem et al. 2013a). Fatty acids in milk fat
originate from two sources, either by direct incorpora-
tion from the peripheral circulation or from de novo
synthesis in the mammary gland using short-chain (2:0
and 4:0) precursors. Mammary de novo synthesis
accounts for all 4:0 to 12:0 fatty acids, most of the
14:0 and typically about half of 16:0 secreted in milk,
while all 18:0 and longer-chain fatty acids are derived
entirely from circulating plasma lipids (Hawke & Tay-
lor 1995). Modification of the fatty acid profile of
milk offers a strategy for lowering the population’s
Table 3 The effect of diets high or low in fat and calcium (Ca) on
faecal losses of fat, calcium and bile acids (from Lorenzen & Astrup
2011)
Faecal losses
High fat Low fat P for
Low Ca High Ca Low Ca High Ca Ca Fat
Fat (g/day) 6.6 11.3 5.5 8.0 *** **
Ca (mg/day) 549 2477 576 2478 *** NS
Bile acid (lmol/day) 274 393 178 346 ** NS
***P <0.001; **P <0.01; NS: non-signiﬁcant P >0.05.
© 2017 The Authors. Nutrition Bulletin published by John Wiley & Sons Ltd on behalf of British Nutrition Foundation Nutrition Bulletin, 42, 274–282
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intake of SFA, by reducing SFA in the food chain,
whilst preserving the beneficial contributions that
dairy products make to the protein and micronutrient
content of the human diet (Kliem & Givens 2011).
Over 100 studies have explored the potential of par-
tially replacing milk SFA with cis-MUFA or cis-PUFA
through supplementation of the dairy cow diet with
plant oils or oilseeds (Glasser et al. 2008). Broadly,
the target is to increase the supply of long-chain fatty
acids (of chain length 18 carbons and above) to the
mammary gland, which inhibit the synthesis of short-
and medium-chain SFA (Givens & Shingfield 2006).
The inclusion of oilseeds in cows’ diets typically pro-
duces reductions in the SFA content of 100 g of milk
fat from 70 g to between 55 and 60 g (Givens &
Shingfield 2006). One study in the EU-funded LIP-
GENE project (involving BNF and the University of
Reading) examined the effect of form of rapeseed lipid
in the diet of the dairy cow on the reduction in milk
SFA and increase in cis-MUFA that could be achieved
(Givens et al. 2009). The cows’ diet treatments were
no rapeseed lipid (control) or rapeseed lipid in the
form of rapeseed oil, whole, unprocessed rapeseeds or
milled rapeseeds. The inclusion of 49 g of rapeseed oil
per kg of dry matter in the diet for a 28-day period
increased cis-MUFA from 23 to 29 g per 100 g of
milk fat, while reducing SFA from 70 to 56 g per
100 g of milk fat. It is clear that using whole, unpro-
cessed rapeseed is not a viable option but the other
two rapeseed lipid forms reduced SFA (notably 16:0)
and increased cis-MUFA (notably cis-18:1). As part of
the Biotechnology and Biological Sciences Research
Council Diet and Health Research Industry Club
(BBSRC DRINC) funded series of studies, Kliem et al.
(2013b) showed that increasing amounts of an experi-
mental calcium salt of cis-MUFA in the cows’ diet
produced a linear reduction in SFA and a linear
increase in cis-MUFA in the milk fat. A summary of
these results is shown in Table 4. The recent study of
Markey et al. (2015a) showed similar changes in the
composition of milk fat as a result of using high oleic
sunflower oil in the diet of the cow.
As seen in Table 4, the inclusion of unsaturated
fatty acids in the dairy cow diet can lead to increased
concentrations of naturally produced ruminant trans-
fatty acids (rTFA), predominantly trans-MUFA, in the
milk. The intake of trans-fatty acids (TFA) from
industrially hydrogenated vegetable oils is known to
substantially increase the risk of CVD (de Souza et al.
2015) and, as a result, there has been a substantial
reduction in the amount of industrial TFA (iTFA) in
the UK food chain (SACN 2007). The association
between rTFA and CVD risk has lacked good experi-
mental evidence although negative associations
between plasma trans-palmitoleic acid (trans-16:1n-7)
concentration (assumed to be mainly of dairy origin)
and type 2 diabetes have been reported (Mozaffarian
et al. 2010, 2013). The recent meta-analysis by de
Souza et al. (2015) reported that intake of iTFA, but
not rTFA, was positively associated with CHD mortal-
ity and risk of CHD, and intake of rTFA inversely
associated with risk of type 2 diabetes. Clearly, there
is a need for more RCT-based evidence on the impact
of rTFA in particular.
Does replacing saturated fatty acids in dairy products
provide health benefits?
Based on the long-standing association between SFA
intake and plasma cholesterol, it would seem that
changing the fatty acid composition of dairy foods to
replace some SFA with cis-PUFA and/or cis-MUFA
could provide a useful way to reduce SFA intake
whilst retaining the nutritional and cardiometabolic
Table 4 Effect of calcium salts of cis-monounsaturated fatty acids (MUFA) supplementation on key milk fatty acid families (g/100 g total fatty
acids; from Kliem et al. 2013b)
Fatty acids
Treatments* P† for
Control CS2 CS4 CS6 SEM Diet Linear Quadratic
Σ SFA 71.0 63.1 57.1 51.6 1.66 <0.001 <0.001 0.008
Σ cis-MUFA 19.9 24.4 26.7 30.8 0.91 <0.001 <0.001 0.073
Σ trans total 6.1 9.6 12.9 15.6 0.74 <0.001 <0.001 <0.001
Σ trans-MUFA 4.3 6.2 8.7 10.5 0.22 <0.001 <0.001 0.691
Σ n-6 PUFA 3.1 3.0 3.1 3.2 0.20 0.048 0.033 0.050
Σ n-3 PUFA 0.40 0.41 0.42 0.38 0.013 0.001 0.054 <0.001
*Where CS2, CS4 and CS6 are diets containing 20, 40 and 60 g/kg diet dry matter calcium salt, respectively; SEM, standard error of the mean.
†Signiﬁcance of overall effect of diet and/or linear/quadratic responses.
© 2017 The Authors. Nutrition Bulletin published by John Wiley & Sons Ltd on behalf of British Nutrition Foundation Nutrition Bulletin, 42, 274–282
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benefits of milk. Indeed, using published models of
cholesterol responses to SFA intake, it was predicted
that, in the EU, reductions of some 10 500 and 3900
deaths from CHD and stroke per annum, respectively,
could result from such a strategy (Givens 2008),
although it is now clear that such a simple model is
not likely to apply to all dairy foods for some of the
reasons discussed above.
Livingstone et al. (2012) reviewed the RCT-based
evidence on the effect on CVD risk markers of con-
suming dairy products modified by changing the nutri-
tion of the dairy cow. Of the nine RCT studies
identified, most used modified butter as the main test
food and change in blood cholesterol was used as the
primary risk marker. Of the six comparable studies
that measured blood cholesterol, five and four
reported significant reductions in TC and LDL-C,
respectively, one showed a rise in TC and two showed
no effect on LDL-C following chronic consumption of
modified milk and dairy products. One study (Seidel
et al. 2005) was of particular interest as it was the
only study to compare the effects of modified dairy
products in normocholesterolaemic (NC) and hyper-
cholesterolaemic (HC) subjects. Dairy cows were fed a
diet containing cis-MUFA-rich rapeseed cake to
achieve the changes in milk fatty acid concentrations
and the milk was used to produce butter and yogurt.
In a 13-week, three-phase, randomised, crossover,
controlled study, subjects were fed modified milk, but-
ter and yogurt, as well as non-modified milk, mar-
garine and yogurt. The results showed that, overall,
LDL-C was reduced (0.38 mmol/l; P <005) and
HDL-C was increased (+033 mmol/l; P <005) when
the modified products were consumed, resulting in a
reduced LDL:HDL ratio (0.43 mmol/l; P <0.05).
These changes were seen in both the HC and NC sub-
jects, interestingly, with greater change in the NC sub-
jects. Seidel et al. (2005) proposed that this may be
due to lipid metabolism in HC subjects being more
complex and/or dietary intervention being less
effective.
As discussed earlier, it is now clear that the use of a
single marker (e.g. blood cholesterol) for predicting
the cardiometabolic risk/benefit associated with con-
sumption of fatty acid-modified dairy foods may not
be adequate and that a wider range and more holistic
markers are needed. A study of this type is presently
underway at the University of Reading in the REplace-
ment of SaturatEd fat in dairy on Total cholesterol
(RESET) study (ClinicalTrials.gov NCT02089035) – a
3.5-year project funded by the UK Medical Research
Council. It is investigating the impact of reducing SFA
in milk and dairy products on vascular function and a
wide range of CMD risk biomarkers, after both acute
and chronic consumption. Some early findings on the
fatty acid composition of the dairy foods used were
presented by Markey et al. (2015a) and on consumer
acceptance of the SFA reduced milk, cheese and butter
by Markey et al. (2015b). The blinded consumer test
indicated that most consumers preferred the conven-
tional products. This suggests that further develop-
ment of modified dairy foods is needed to ensure they
are acceptable to consumers. This would need to be
accompanied by clear health-related information to
allow consumers to make informed decisions on pur-
chase and consumption.
Conclusions
It is now clear that the effects of reducing dietary SFA
are best interpreted by an understanding of which
macronutrients replace them, with reduced CVD risk
being associated with the replacement of SFA with cis-
PUFA and cis-MUFA. Most judgements have, how-
ever, been made using TC/LDL-C as the primary
markers of CVD risk, and because of potentially coun-
terbalancing effects in dairy food (e.g. effect of protein
on blood lipids and blood pressure; matrix effects on
fat bioavailability), a wider range of markers are
needed. Nevertheless, whilst prospective evidence
shows no increase in CVD risk from high dairy con-
sumption, it is still unclear whether replacing a pro-
portion of SFA in dairy fat with cis-MUFA will lead
to reduced CVD risk. The relatively few RCTs that
have examined this, using TC/LDL-C as the risk mar-
ker, provide some indication of reduced CVD risk
from consumption of milk and dairy products with
modified fatty acid composition, compared with those
of normal milk fat composition. The results of ongo-
ing studies will add valuable new evidence on this
issue.
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